NIPPON CHEMIPHAR CO., LTD. (4539) Stock Price

Nippon Chemiphar is a company centered on the manufacture and sale of pharmaceutical products for medical use. The company is composed of six entities, including four consolidated subsidiaries and one affiliated company, and operates in medical, health, and beauty-related businesses. Through this structure, it provides a wide range of services centered on the manufacture and sale of pharmaceuticals.

The company's business is divided into two main segments. First, in the pharmaceutical business, it manufactures and sells prescription pharmaceuticals. This segment involves Nippon Yakuhin Kogyo Co., Ltd., Nippon Chemiphar Vietnam Co., Ltd., and Japan Sofarsim Co., Ltd.

The second segment is other businesses. This includes contract safety testing services, healthcare operations, and real estate rental operations. This segment involves Compound Safety Research Institute Co., Ltd. and Shapro Co., Ltd. Through this diversified business approach, Nippon Chemiphar realizes multiple revenue streams.

Nippon Chemiphar is guided by the management philosophy of "contributing to people's healthy and enriched lives through comprehensive healthcare centered on pharmaceuticals." The company aims to develop as a corporate group with meaningful presence both domestically and internationally, while strengthening its leadership in the pharmaceutical industry.

The company's medium to long-term management strategy centers on three business domains: "generic pharmaceuticals," "clinical diagnostic reagents," and "new drug development." The company is actively expanding these businesses into overseas markets to achieve global growth. In particular, it is focusing on improving the quality and ensuring stable supply of generic pharmaceuticals.

Nippon Chemiphar is strengthening its generic pharmaceutical supply system through increased manufacturing personnel and capital investment. To improve sales efficiency, the company is enhancing B2B capabilities and promoting customer management using AI technology. These efforts secure competitive advantage in an increasingly competitive market.

In the clinical diagnostic reagent field, the company is advancing domestic and international adoption of its allergy screening device "DropScreen." Domestically, it aims to increase cumulative unit installations, while also considering expansion into overseas markets. Through product improvements and manufacturing cost reduction, the company is enhancing customer satisfaction.

In new drug development, the company is focusing on alkalization therapy agents and proprietary drug discovery. Specifically, it is advancing new drug development in oncology and chronic kidney disease areas, aiming to provide innovative treatments. The company is also promoting research and development utilizing AI technology to achieve efficient new drug development.

For international expansion, the company has obtained approvals for eight products in four countries including China and is conducting sales. By fiscal year 2026, it aims to expand to five countries with 14 products, strengthening its market presence locally. The company is also considering entry into the Middle East and Africa regions, conducting market research through cooperation with the International Finance Corporation.